Purpose Inadequate piperacillin (PIP) exposure in intensive care unit (ICU) patients
threatens therapeutic success. Model-informed precision dosing (MIPD) might be promising …

Introduction Older individuals face an elevated risk of developing bacterial infections. The
optimal use of antibacterial agents in this population is challenging because of age-related …

Introduction Population pharmacokinetic studies of β-lactam antimicrobials in critically ill
patients derive models that inform their dosing. In non-linear mixed-effects modelling …

Piperacillin/tazobactam (TZP) is administered intravenously in a fixed ratio (8: 1) with the
potential for inadequate tazobactam exposure to ensure piperacillin activity against …

Severe community-acquired pneumonia (CAP) is a condition that frequently requires
intensive care and, eventually, can cause to death. Piperacillin/tazobactam antibiotic therapy …

Objectives WCK 4282 is a novel combination of cefepime 2 g and tazobactam 2 g being
developed for the treatment of infections caused by piperacillin/tazobactam-resistant ESBL …

Objective To develop and validate an UPLC–MS/MS assay for simultaneous determination
of the total concentration of ceftazidime, ciprofloxacin, flucloxacillin, piperacillin, tazobactam …

Population pharmacokinetic (pop-PK) models constructed for model-informed precision
dosing often have limited utility due to the low number of patients recruited. To augment …

Objective There is a paucity of published data to evaluate the efficacy and safety of
imipenem, cefepime and piperacillin/tazobactam dosing regimens against bloodstream …

Critically ill patients undergo significant pathophysiological changes that affect antibiotic
pharmacokinetics. Piperacillin/tazobactam administered by continuous infusion (CI) …